Login to Your Account



L-annamycin firing pin? Moleculin IPO to garner up to $12M for AML drug

By Randy Osborne
Staff Writer

Wednesday, May 4, 2016

Things may soon be looking up for liposomal anthracycline L-annamycin, in the works for AML, if Moleculin Biotech Inc. has anything to say about it.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription